China leaves Merck in need of a new profit injection
Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...
STAT10d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
FiercePharma3d
UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
The Associated Press - Business News on MSN10d
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck KGaA verhandelt Milliardendeal mit US-Tumorspezialisten
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
pharmaphorum2d
With Merck circling, SpringWorks gets new drug approval
Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...